Investors are always looking for stocks that are poised to beat at earnings season and Neurocrine Biosciences, Inc. NBIX may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Neurocrine Biosciences is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for NBIX in this report.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,